Pérez-Alba Eduardo, Nuzzolo-Shihadeh Laura, Aguirre-García Gloria Mayela, Espinosa-Mora Jaime, Lecona-Garcia Juan Diego, Flores-Pérez Romulo Omar, Mendoza-Garza Marisela, Camacho-Ortiz Adrián
Servicio de Infectología, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico; Coordinación de Epidemiología, Servicio de Infectología, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico.
Servicio de Infectología, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico.
J Microbiol Immunol Infect. 2021 Oct;54(5):787-793. doi: 10.1016/j.jmii.2021.05.009. Epub 2021 Jul 3.
We aimed to analyze clinical outcomes from patients with severe COVID-19 pneumonia that received either baricitinib plus dexamethasone or dexamethasone monotherapy.
We performed a retrospective comparative study. Data from hospitalized patients with severe COVID-19 pneumonia (saturation <93%, bilateral pulmonary infiltrates) that were treated with baricitinib plus dexamethasone or dexamethasone were collected. Our primary objective was to compare overall mortality and secondly to compare progression to mechanical ventilation and over infection rates.
A total of 793 patients were assessed for inclusion criteria, 596 were excluded and 197 were analyzed for primary outcome: 123 in the baricitinib plus dexamethasone group and 74 in the dexamethasone monotherapy group. The mean age was 59.9 years (SD ± 14.5) and 62.1% (123/197) were male. 42.9% (85/197) of the cases required ICU admission and 25.8% (51/197) underwent invasive mechanical ventilation (IMV). Overall thirty-day mortality was 27.9% (55/197); Mortality was significantly lower in the baricitinib plus dexamethasone group compared to the dexamethasone monotherapy group (20.3% vs 40.5%, P = <.05). There was no difference in hospital acquired infections between both groups.
Thirty-day mortality was significantly lower in patients with COVID-19 pneumonia treated with baricitinib plus dexamethasone versus dexamethasone monotherapy. No difference was observed in progression to invasive mechanical ventilation and hospital acquired infections.
我们旨在分析接受巴瑞替尼联合地塞米松或地塞米松单药治疗的重症新型冠状病毒肺炎患者的临床结局。
我们进行了一项回顾性对照研究。收集了因重症新型冠状病毒肺炎（血氧饱和度<93%，双侧肺部浸润）住院并接受巴瑞替尼联合地塞米松或地塞米松治疗的患者数据。我们的主要目的是比较总体死亡率，其次是比较有创机械通气进展和感染率。
共有793例患者接受纳入标准评估，596例被排除，197例被分析用于主要结局：巴瑞替尼联合地塞米松组123例，地塞米松单药治疗组74例。平均年龄为59.9岁（标准差±14.5），男性占62.1%（123/197）。42.9%（85/197）的病例需要入住重症监护病房，25.8%（51/197）接受有创机械通气（IMV）。总体30天死亡率为27.9%（55/197）；与地塞米松单药治疗组相比，巴瑞替尼联合地塞米松组的死亡率显著更低（20.3%对40.5%，P =<.05）。两组医院获得性感染无差异。
与地塞米松单药治疗相比，接受巴瑞替尼联合地塞米松治疗的新型冠状病毒肺炎患者30天死亡率显著更低。在有创机械通气进展和医院获得性感染方面未观察到差异。
